TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7880610
Drug: Neutralising activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralising activity in patients with anti-rIL-2 antibodies
Study: 7880610
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving at least two cycles of rIL-2 by s.c. injections
Study: 7880610
Drug: Development of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development of anti-rIL-2 antibodies
Study: 29396245
Drug: Azathioprine (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (100-200 mg per day for 48 weeks)
Study: 20230389
Drug: Docetaxel reintroduction
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel reintroduction as second-line therapy
Study: 9068935
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg/day titrated to 200 mg/day for 32 days
Study: 8415898
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg, P.O.)
Study: 27443570
Drug: Integrated orthogeriatric
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated orthogeriatric treatment
Study: 23384428
Drug: Enzogenol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzogenol (1000 mg/day)
Study: 9303253
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy group program for headaches; two 90-minute sessions focusing on relaxation, distraction, visualization, and stress management skills.
Study: 9303253
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy group program for headaches; two 90-minute sessions.
Study: 9303253
Drug: Follow-up ratings
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up ratings from parents after treatment.
Study: 8314199
Drug: Semilente (amorphous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semilente (amorphous zinc insulin) injected at bedtime
Study: 27094506
Drug: Standard-dose (SD)
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (SD) group: 40 µg total vaccine dose, 20 µg at weeks 0 and 4
Study: 27094506
Drug: High-dose dose-intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dose-intensive (HDDI) group: 80 µg total vaccine dose, 40 µg at weeks 0 and 4
Study: 27094506
Drug: High-dose time-intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose time-intensive (HDTI) group: 80 µg total vaccine dose, 20 µg at weeks 0, 2, 4, and 6
Study: 25058879
Drug: PDP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDP with ET‐Kyoto solution
Study: 25058879
Drug: PDP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDP with cold storage/purification stock solution
Study: 25058879
Drug: PDP groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDP groups (both solutions)
Study: 21644
Drug: Melperone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melperone 100 mg X 3
Study: 21644
Drug: Thiothixene 10
Normalized name: thiothixene 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiothixene 10 mg X 3
Study: 1831016
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg IV)
Study: 19559297
Drug: Lactobacillus rhammosus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhammosus GG (minimum dose, 10 degrees bacteria)
Study: 16432349
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 500 mg intravenously before operation followed by 250 mg every 6 hours for 3 days
Study: 15514192
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg per day)
Study: 15514192
Drug: Fosinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (20 mg per day)
Study: 15514192
Drug: Hydrochlorothiazide plus
Normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide plus Pravastatin (40 mg per day)
Study: 15514192
Drug: Fosinopril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril plus Pravastatin (40 mg per day)
Study: 12748465
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine injection
Study: 2663159
Drug: Ciclopirox olamine
Normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox olamine lotion 1%
Study: 31216215
Drug: Ketorolac (10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (10-mg tablets every 8 h)
Study: 31216215
Drug: Gabapentin (300-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300-mg capsules every 8 h)
Study: 26946615
Drug: Bloodletting therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bloodletting therapy at local myofascial trigger points and acupuncture at Jiaji (EX-B 2) points
Study: 26946615
Drug: Lidocaine block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine block therapy
Study: 17645494
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional intravenous treatment)
Study: 15702859
Drug: L. plantarum
Normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. plantarum 299v in an oatmeal-fermented drink (10(9) CFU/ml) given twice daily
Study: 11790498
Drug: 99mTc‐labelled lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐labelled lactose inhaled at four inspiratory flows (30, 40, 60, and 80 l/min)
Study: 7573260
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg twice a day, slow-release capsules)
Study: 2406228
Drug: Positive Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive Radiation Group (PRG): further irradiation to a total dose of 90 Gy by the cone‐down and assault technique.
Study: 6768079
Drug: Apomorphine (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (continuous IV infusion for 180-240 min)
Study: 6768079
Drug: Post-infusion period
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-infusion period (240 min after apomorphine infusion)
Study: 6768079
Drug: Haloperidol or
Normalized name: haloperidol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol or sulpiride (dopamine receptor blocking agents)
Study: 24787908
Drug: Cholecalciferol (800,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (800,000 IU, 4000 IU daily)
Study: 19857313
Drug: Antibiotics for
Normalized name: ANTIBIOTICS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for mild diverticulitis
Study: 16351775
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate syrup (20 mg elemental Fe twice daily)
Study: 12438475
Drug: Two weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two weeks of prednisolone 20 mg daily followed by two weeks of prednisolone 10 mg daily (n = 53)
Study: 12438475
Drug: Two weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two weeks of prednisolone 20 mg daily and two weeks of placebo (n = 56)
Study: 9389675
Drug: Urodilatin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urodilatin infusion (40 ng / kg bw / min for 6 days)
Study: 28170279
Drug: 74 g
Normalized name: WATER 99.9974 g in 100 L ORAL LIQUID [37.4]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 74 g raisins
Study: 22287379
Drug: Point-of-care computed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care computed tomography (POC-CT) at the initial visit followed by medical therapy based on CT results (pre-CT group)
Study: 22287379
Drug: Empiric medical
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric medical therapy (EMT) followed by POC posttreatment CT if symptoms persisted (EMT group)
Study: 22287379
Drug: Empiric medical
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric medical therapy (EMT)
Study: 22287379
Drug: Overall prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall prescriptions costs
Study: 17880502
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 5% ALA solution
Study: 17880502
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 10% ALA solution
Study: 17880502
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 0.5%, 1%, 3%, 5%, or 10% ALA solution
Study: 17880502
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of ALA solution
Study: 9933475
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation (500 mg/day of elemental calcium and 700 IU/day of cholecalciferol)
Study: 2196962
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg doxycycline
Study: 7356102
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with 5‐fluorouracil, vinblastine, and cyclophosphamide
Study: 29884572
Drug: Ethanol lock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol lock therapy (70% ethanol)
Study: 24000106
Drug: Weaning from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weaning from a convective incubator at 1,500 g body weight
Study: 24000106
Drug: Weaning from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weaning from a convective incubator at 1,600 g body weight (control)
Study: 24000106
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (1,500 g and 1,600 g)
Study: 20506226
Drug: Intravenous autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous autologous ex vivo cultured MSCs (MSC group)
Study: 20506226
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no MSC treatment)
Study: 15820237
Drug: Bupropion XL
Normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion XL (up to 450 mg/day)
Study: 29724865
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus administration of 400 µg TRH
Study: 29724865
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL saline)
Study: 27187893
Drug: Varenicline (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (active pill plus placebo patch)
Study: 27187893
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (active patch plus placebo pill)
Study: 27187893
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo pill plus placebo patch)
Study: 24756119
Drug: Multipurpose solution
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multipurpose solution
Study: 17828765
Drug: 3-week control
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week control group instructed in writing about daily activities
Study: 15668602
Drug: Fortified skimmed
Normalized name: Calcium fortified skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified skimmed milk containing 1,200 mg of calcium and 5.7 microg of vitamin D (group A)
Study: 15668602
Drug: Fortified skimmed
Normalized name: Calcium fortified skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified skimmed milk containing 900 mg of calcium and 5.7 microg of vitamin D (group B)
Study: 11881794
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 150 IU/kg or 300 IU/kg, administered 3 times weekly for 28 weeks
Study: 7731768
Drug: iohexol 140
Normalized name: iohexol 140 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 140 mgI/ml
Study: 21189381
Drug: Intravenous calcium/magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous calcium/magnesium (1g calcium gluconate plus 1g magnesium sulfate pre‐ and post‐oxaliplatin)
Study: 21189381
Drug: Intravenous calcium/magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous calcium/magnesium
Study: 10940745
Drug: Daily prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisone for 5 days during upper respiratory infection (URI)
Study: 9737626
Drug: Ifetroban (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifetroban (250 mg daily)
Study: 7920954
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ranitidine (0.15 mg/kg bolus followed by 0.15 mg/kg/hour for 12 hours)
Study: 7920954
Drug: Bolus dosing
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dosing of ranitidine (1 mg/kg, two doses 6 hours apart)
Study: 7920954
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (continuous infusion and bolus dosing)
Study: 3401271
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bisacodyl solution
Study: 3401271
Drug: Dulcolax Dragees
Normalized name: Dulcolax
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulcolax Dragees (2 x 5 mg)
Study: 3401271
Drug: Dulcolax suppository
Normalized name: bisacodyl Rectal Suppository [Dulcolax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulcolax suppository (10 mg)
Study: 20470848
Drug: ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone 40 mg BID for 2 days, titrated up to 80 mg BID thereafter
Study: 20470848
Drug: abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: abrupt discontinuation of conventional antipsychotics
Study: 20470848
Drug: fast taper-50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: fast taper-50% of conventional antipsychotic dosage on days 1 through 7, followed by discontinuation
Study: 20470848
Drug: slow taper-100%
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow taper-100% of conventional antipsychotic dosage on days 1 and 2, followed by 50% on days 3 through 7, then discontinuation
Study: 18262432
Drug: Acetyl salicylic
Normalized name: Acetyl salicylic acid specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl salicylic acid (100 mg/die) and atorvastatin (10 mg/die) combined treatment
Study: 16456725
Drug: Advice to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice to eat fatty fish or fish oil capsules (DART)
Study: 16456725
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (DART 2)
Study: 2628313
Drug: Oral prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prostaglandin E2 tablets (0.5-1.5 mg hourly)
Study: 2628313
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (starting at 2 mU/min, max 64 mU/min)
Study: 30286004
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (based on the combination of transverse diameter of cricoid ring and ED-LMB)
Study: 30468986
Drug: Community-based cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based cohort (CC) participants
Study: 30468986
Drug: Participants on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants on psychiatric treatment
Study: 19925973
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic alone (40 mL)
Study: 11464356
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic plus buprenorphine (0.3 mg)
Study: 7809537
Drug: Itraconazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (6 mg/kg/day for 120 days)
Study: 7809537
Drug: Allopurinol (8.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (8.5 mg/kg/day for 60 days)
Study: 3422261
Drug: Short-term chemotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term chemotherapy with Adriamycin (ADR), cytarabine (ara-C), and thioguanine (TG) for 6 cycles
Study: 3422261
Drug: Short-term chemotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term chemotherapy with Adriamycin (ADR), cytarabine (ara-C), and thioguanine (TG)
Study: 28007348
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (conventional or sensor-augmented insulin pump therapy)
Study: 28806095
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PRP injections)
Study: 23456672
Drug: IM clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM clodronate 100 mg twice weekly (Group B)
Study: 23456672
Drug: IM clodronate
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM clodronate 100 mg once weekly (Group A)
Study: 20163263
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium patch
Study: 16301721
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of water ingestion before ultrasonographic examination (Group A)
Study: 16301721
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of water ingestion (Group A)
Study: 9793190
Drug: GnRH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH analog plus oral contraceptive (OC) therapy
Study: 9793190
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) therapy alone
Study: 7657122
Drug: Tamoxifen, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen, 20 mg/day per os (group A)
Study: 2568711
Drug: alpha-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-agonist
Study: 2568711
Drug: pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: pharmacological treatment
Study: 364917
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel (1 mg in viscous gel)
Study: 31279865
Drug: Aloysia polystachya
Normalized name: Aloysia citrodora flower oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloysia polystachya powdered leaves (300 mg, twice a day)
Study: 16460294
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg for infants under 12 months, 40 mg for older children)
Study: 10648454
Drug: Mesalamine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine (4 g daily for 18 months)
Study: 10648454
Drug: Mesalamine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine (4 g daily for 18 months) in isolated small bowel disease subgroup
Study: 9308977
Drug: High-dose pyridoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pyridoxine (30 or 50 mg/kg/day) by intravenous infusion
Study: 3548301
Drug: Sustained-release diltiazem,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release diltiazem, 120 to 180 mg twice daily
Study: 3548301
Drug: Hydrochlorothiazide, 25
Normalized name: HydroCHLOROthiazide, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 25 to 50 mg twice daily
Study: 3548301
Drug: Hydrochlorothiazide, 50
Normalized name: HydroCHLOROthiazide, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 50 mg/day
Study: 30342255
Drug: Newsletter program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newsletter program (monthly mailings and family-focused healthy lifestyle information)
Study: 26464170
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available drug treatment (group B; N=261 patients)
Study: 22197071
Drug: C1-inhibitor concentrate
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor concentrate (C1-INH)
Study: 22197071
Drug: C1-inhibitor concentrate
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor concentrate (C1-INH-NF)
Study: 21153932
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (listening to music through headphones for one hour after surgery)
Study: 18764771
Drug: ETR (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETR (400 mg or 800 mg twice daily)
Study: 18764771
Drug: ETR (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETR (800 mg or 1200 mg twice daily)